Intra‐operative cisplatin for the treatment of canine extremity soft tissue sarcomas

M. Havlicek, R. S. Straw, Veronika Langová, W. S. Dernell

Veterinary and Comparative Oncology · 2009 · 19 citations · 26 references

Concepts

Abstract

Abstract Nineteen dogs with histologically confirmed soft tissue sarcomas of the extremities were treated with a combination of marginal surgery and intra‐operative chemotherapy in the form of cisplatin in a biodegradable implant delivery system (Atrigel ® ; Atrix Laboratories, Fort Collins, Co, USA). None of the dogs had evidence of metastasis at time of treatment. The median dose of cisplatin was 52.1 mg/m 2 (mean 55.4 mg/m 2 , range 18.5–108.6 mg/m 2 ). Wound complications were noted in 16 dogs (84.2%). Median follow‐up time was 874 days (mean 777 days, range 125–1463 days). Nine dogs (47.3%) were alive at the time of analysis. Local recurrence occurred in three dogs (16.6%). The time to recurrence was 214, 264 and 874 days.

References

26